A Commitment to Impact
Pi Health is dedicated to making clinical research inclusive, efficient, and impactful. Our mission is to eliminate barriers, accelerate breakthrough therapies, and ensure diverse patient populations benefit from innovative medical advances.
Leadership
Geoff Kim, MD
Co-founder, CEO
Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of Pi Health, a healthcare technology company launched in 2021 whose mission is to drive innovation to enable patients all over the world to have equal access to the highest quality of care and research. He has over 25 years of experience in oncology drug development, regulation, and precision medicine.
As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.
Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.
As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.
Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.
Bobby Reddy, MD
Co-founder, COO
Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world.
Previously, he served in leadership positions at BeiGene and AstraZeneca. At BeiGene, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Previously, he served in leadership positions at BeiGene and AstraZeneca. At BeiGene, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Kevin Stenerson
Head of Technology
Kevin Stenerson is the VP of Engineering at Pi Health, where he leads the engineering and development of the company's AI-driven clinical research platform. With over 15 years of experience building and scaling technology organizations, he brings a proven track record of transforming engineering teams and delivering systems that create meaningful impact in healthcare and enterprise software.
Most recently, Kevin served as Senior Director and Principal Engineer at AuditBoard, where he played a pivotal role in the company's dramatic growth trajectory. During his tenure, he scaled the engineering organization from 25 to over 100 engineers, architected high-performance systems that supported platform revenue growth from $17M to over $170M, and established engineering management processes that enabled sustainable scale. His technical leadership and organizational development contributed significantly to AuditBoard's successful $3 billion acquisition by HG in July 2024.
Kevin's expertise in healthcare technology reflects years of developing solutions for patient care. At Reflexion Health, he developed innovative telemedicine technology in collaboration with Mayo Clinic and other leading healthcare institutions. His work on physical therapy solutions for post-surgical knee and hip replacement patients enabled earlier hospital discharge and improved therapy adherence. The technology used computer vision AI to guide patients safely through home exercises while automatically flagging movement deficits to clinicians, making specialized care accessible to patients in distant and rural communities who would otherwise struggle with post-operative care access.
At Flint Clinical, Kevin served as Head of Engineering, where he built software solutions that streamlined clinical trial budgeting for biotechnology companies and clinics specializing in dermatology.
Beyond healthcare, as Co-Founder of Wyyerd Fiber, Kevin established a telecommunications company focused on bringing fiber-to-the-home services to markets dominated by legacy providers. He led the company through its initial capital raise, developed greenfield markets, and oversaw the acquisition and expansion of fiber infrastructure in Phoenix, Arizona, before successfully exiting during a subsequent funding round.
Throughout his career, Kevin has driven successful outcomes across diverse industries including healthcare technology, enterprise SaaS, telecommunications, regulatory compliance systems, and payment platforms. His experience spans founding startups, scaling engineering teams at billion-dollar companies, and building technology that creates lasting impact.
Kevin holds a B.S. from the University of Colorado Boulder. He believes in building systems that scale, teams that innovate, and technology that serves a larger purpose - whether improving patient outcomes, enabling economic growth, or opening new possibilities for innovation.
Most recently, Kevin served as Senior Director and Principal Engineer at AuditBoard, where he played a pivotal role in the company's dramatic growth trajectory. During his tenure, he scaled the engineering organization from 25 to over 100 engineers, architected high-performance systems that supported platform revenue growth from $17M to over $170M, and established engineering management processes that enabled sustainable scale. His technical leadership and organizational development contributed significantly to AuditBoard's successful $3 billion acquisition by HG in July 2024.
Kevin's expertise in healthcare technology reflects years of developing solutions for patient care. At Reflexion Health, he developed innovative telemedicine technology in collaboration with Mayo Clinic and other leading healthcare institutions. His work on physical therapy solutions for post-surgical knee and hip replacement patients enabled earlier hospital discharge and improved therapy adherence. The technology used computer vision AI to guide patients safely through home exercises while automatically flagging movement deficits to clinicians, making specialized care accessible to patients in distant and rural communities who would otherwise struggle with post-operative care access.
At Flint Clinical, Kevin served as Head of Engineering, where he built software solutions that streamlined clinical trial budgeting for biotechnology companies and clinics specializing in dermatology.
Beyond healthcare, as Co-Founder of Wyyerd Fiber, Kevin established a telecommunications company focused on bringing fiber-to-the-home services to markets dominated by legacy providers. He led the company through its initial capital raise, developed greenfield markets, and oversaw the acquisition and expansion of fiber infrastructure in Phoenix, Arizona, before successfully exiting during a subsequent funding round.
Throughout his career, Kevin has driven successful outcomes across diverse industries including healthcare technology, enterprise SaaS, telecommunications, regulatory compliance systems, and payment platforms. His experience spans founding startups, scaling engineering teams at billion-dollar companies, and building technology that creates lasting impact.
Kevin holds a B.S. from the University of Colorado Boulder. He believes in building systems that scale, teams that innovate, and technology that serves a larger purpose - whether improving patient outcomes, enabling economic growth, or opening new possibilities for innovation.
Chao Liu, PhD
Chief Financial Officer
Dr. Chao Liu, as the Chief Financial Officer and a Founding Member of Pi Health since September 2021, plays a critical role in steering the company's strategic financial direction. Based in the Washington DC-Baltimore area, his expertise is central to Pi Health's mission of revolutionizing clinical research globally through cutting-edge technology.
Before his current role at Pi Health, Dr. Liu served as Senior Director of Applied Innovation Quantitative Solutions at BeiGene. His impactful work included creating and delivering tailored analytic solutions, performing market assessments and real-time valuations, implementing innovative technology in oncology therapeutic development.
Prior to BeiGene, Liu was part of the Food and Drug Administration (FDA) from September 2014 to December 2019. He started as a Reviewer in Clinical Pharmacology/Pharmacometrics and later became a Team Leader in the same division. His focus areas included oncology, hematology, infectious diseases, cardiovascular, and renal diseases. At the FDA, Dr. Liu was responsible for overseeing high-quality and timely reviews of NDA and IND submissions, supervising and mentoring review teams, and leading research projects in regulatory sciences. In addition, he led or participated in the drafting and publication of multiple FDA guidance for industry.
Dr. Liu's journey through these diverse roles reflects a deep commitment to advancing the integration of financial strategy with healthcare innovation. His expertise in quantitative analysis and regulatory sciences, coupled with his financial acumen, positions him as a key driver in Pi Health's pursuit of transforming clinical research infrastructure on a global scale.
Before his current role at Pi Health, Dr. Liu served as Senior Director of Applied Innovation Quantitative Solutions at BeiGene. His impactful work included creating and delivering tailored analytic solutions, performing market assessments and real-time valuations, implementing innovative technology in oncology therapeutic development.
Prior to BeiGene, Liu was part of the Food and Drug Administration (FDA) from September 2014 to December 2019. He started as a Reviewer in Clinical Pharmacology/Pharmacometrics and later became a Team Leader in the same division. His focus areas included oncology, hematology, infectious diseases, cardiovascular, and renal diseases. At the FDA, Dr. Liu was responsible for overseeing high-quality and timely reviews of NDA and IND submissions, supervising and mentoring review teams, and leading research projects in regulatory sciences. In addition, he led or participated in the drafting and publication of multiple FDA guidance for industry.
Dr. Liu's journey through these diverse roles reflects a deep commitment to advancing the integration of financial strategy with healthcare innovation. His expertise in quantitative analysis and regulatory sciences, coupled with his financial acumen, positions him as a key driver in Pi Health's pursuit of transforming clinical research infrastructure on a global scale.
Paulo Tioseco
Head of Engineering
Paulo Tioseco is the Senior Director of Engineering at Pi Health, where he leads product development and drives the growth of a high-performing engineering organization. With over a decade of experience in software development and technical leadership, Paulo brings deep expertise in scaling teams and delivering complex technology products.
Before joining Pi Health, Paulo led engineering teams at Amazon, where he played a pivotal role in launching two major initiatives: AWS Outposts and Project Kuiper. At AWS Outposts, his team built services to automate the provisioning of edge computing hardware, scaling from zero to over 100 deployments at customer sites in the first year of general availability. At Project Kuiper, he led the engineering organization that built, from the ground up, the command-and-control systems enabling communication between Amazon’s low Earth orbit satellites and ground stations, a historic first for the company.
Earlier in his career, Paulo held technical and leadership roles at high-growth technology companies such as Space Exploration Technologies (SpaceX), EdgeCast Networks (acquired by Verizon), and Apriso (acquired by Dassault Systèmes). He also co-founded Tourjive, a data analytics startup for the live music industry. Today, he continues to support innovation as an angel investor, with a focus on hardware and AI startups.
While in university, before the advent of modern cloud computing, Paulo conducted research and development on a distributed system to query and retrieve medical images using the DICOM standard (Digital Imaging and Communications in Medicine) from remote hospitals via a central location. With this background and a proven track record of delivering cutting-edge products at scale, Paulo is well-positioned to lead the engineering efforts that enable Pi Health to deliver on its mission to democratize and accelerate clinical trials, and ultimately, to save lives.
Before joining Pi Health, Paulo led engineering teams at Amazon, where he played a pivotal role in launching two major initiatives: AWS Outposts and Project Kuiper. At AWS Outposts, his team built services to automate the provisioning of edge computing hardware, scaling from zero to over 100 deployments at customer sites in the first year of general availability. At Project Kuiper, he led the engineering organization that built, from the ground up, the command-and-control systems enabling communication between Amazon’s low Earth orbit satellites and ground stations, a historic first for the company.
Earlier in his career, Paulo held technical and leadership roles at high-growth technology companies such as Space Exploration Technologies (SpaceX), EdgeCast Networks (acquired by Verizon), and Apriso (acquired by Dassault Systèmes). He also co-founded Tourjive, a data analytics startup for the live music industry. Today, he continues to support innovation as an angel investor, with a focus on hardware and AI startups.
While in university, before the advent of modern cloud computing, Paulo conducted research and development on a distributed system to query and retrieve medical images using the DICOM standard (Digital Imaging and Communications in Medicine) from remote hospitals via a central location. With this background and a proven track record of delivering cutting-edge products at scale, Paulo is well-positioned to lead the engineering efforts that enable Pi Health to deliver on its mission to democratize and accelerate clinical trials, and ultimately, to save lives.
Smruthi Panyam
Head of Clinical Data Strategy and Stewardship
Smruthi Panyam is an accomplished life sciences leader with over 21 years of global experience driving clinical data innovation and operational excellence across the pharmaceutical, biotech, and CRO industries. Currently serving as Vice President of Clinical Data Strategy and Stewardship at Pi Health Inc., she plays a pivotal role in shaping clinical technology infrastructure and strategic data operations. Smruthi brings deep expertise in global clinical trial delivery, regulatory compliance, and data lifecycle management, having successfully led and submitted clinical trials across the U.S., Europe, and Asia.
Renowned for her transformational leadership, Smruthi has consistently delivered clinical trials in accelerated timelines to highest quality. Her portfolio includes leading complex merger and acquisition transitions, orchestrating trial rescue operations, and spearheading enterprise-level process improvements that have boosted trial efficiency, safety oversight, and data quality.
Her previous leadership roles at BeiGene and AstraZeneca saw her champion cross-functional collaboration, innovation, streamline operations, and pioneer automation and technology solutions that significantly improved speed, accuracy, and scalability in data review processes. With a background in dentistry and formal training in Lean, Agile, and Scaled Agile methodologies, Smruthi is a rare blend of clinical insight and technical acumen.
Fluent in English, with working knowledge of Japanese, Polish and German, Smruthi is also a seasoned mentor and team builder, committed to fostering collaborative cultures that elevate both people and performance in pursuit of patient-centric, regulatory compliant, data-driven solutions.
Renowned for her transformational leadership, Smruthi has consistently delivered clinical trials in accelerated timelines to highest quality. Her portfolio includes leading complex merger and acquisition transitions, orchestrating trial rescue operations, and spearheading enterprise-level process improvements that have boosted trial efficiency, safety oversight, and data quality.
Her previous leadership roles at BeiGene and AstraZeneca saw her champion cross-functional collaboration, innovation, streamline operations, and pioneer automation and technology solutions that significantly improved speed, accuracy, and scalability in data review processes. With a background in dentistry and formal training in Lean, Agile, and Scaled Agile methodologies, Smruthi is a rare blend of clinical insight and technical acumen.
Fluent in English, with working knowledge of Japanese, Polish and German, Smruthi is also a seasoned mentor and team builder, committed to fostering collaborative cultures that elevate both people and performance in pursuit of patient-centric, regulatory compliant, data-driven solutions.
Mitch Yarchin
Head of Product
Mitch Yarchin is a startup leader and entrepreneur with over 15 years of experience in healthtech and enterprise SaaS. As founding Head of Product at Preveta, he launched data-driven AI solutions adopted by several leading healthcare organizations in the oncology space. Previously, he led product management at AuditBoard, supporting growth to over $150 million in ARR and successful acquisition. Mitch is known for building high-performing teams, delivering complex data integrations, and driving innovative products that solve real-world problems.
Steve Reyes, PhD
Head of Clinical Operations & Development
Steve Reyes leads the Clinical Operations & Development function enhancing clinical trial efficiency and leveraging technology to drive innovative solutions. He obtained his PhD in Cancer Biology from MD Anderson, researching novel mechanisms of glioblastoma. For over a decade he has optimized operational strategies, integrated transformative technologies into the clinical trial process, and contributed to advancements in clinical trial execution.
Prior to joining Pi Health, Steve oversaw numerous clinical trials and led assets from FIH to approval during his time with LabCorp’s clinical trial division (now Fortrea), Syneos Health, as well as Intellia Therapeutics. Steve is a dedicated and versatile clinical development leader with extensive experience developing therapeutic platforms including gene editing, lipid nanoparticles, small molecules, antibodies, antibody drug conjugates (ADC), adeno-associated viruses (AAV), and cell therapies (autologous and allogeneic). He has built delivery teams that range from biotechs to clinical research organizations (CROs). Known for driving operational excellence from organizational frameworks to individual study execution, Steve has expertise developing assets spanning oncology, rare diseases, gastrointestinal, infectious disease, and cardiovascular indications.
Prior to joining Pi Health, Steve oversaw numerous clinical trials and led assets from FIH to approval during his time with LabCorp’s clinical trial division (now Fortrea), Syneos Health, as well as Intellia Therapeutics. Steve is a dedicated and versatile clinical development leader with extensive experience developing therapeutic platforms including gene editing, lipid nanoparticles, small molecules, antibodies, antibody drug conjugates (ADC), adeno-associated viruses (AAV), and cell therapies (autologous and allogeneic). He has built delivery teams that range from biotechs to clinical research organizations (CROs). Known for driving operational excellence from organizational frameworks to individual study execution, Steve has expertise developing assets spanning oncology, rare diseases, gastrointestinal, infectious disease, and cardiovascular indications.
Ro Wickramasinghe, PhD
Head of Business Development
Dr Ro Wickramasinghe is the Vice President and Global Head of Business Development at Pi Health, where he leads Strategic Partnerships with Pharmaceutical and Biotech sponsors, as well as with Clinical Trial Sites. He also oversees Pi Health’s Business Operations across Australia and Europe.
Ro is a seasoned industry leader and brings over 15 years of experience in Business Development roles across the Pharma, Biotech, and HealthTech sectors. His career includes multiple leadership roles, with a consistent track record of executing transformative deals that have helped shape Standards of Care in Oncology.
At BeiGene, where Pi Health was originally incubated, Ro led Commercial and Business Development within the Applied Innovation Group. Prior to that, as Vice President and Head of Business Development at Ellipses Pharma, he built out key functions - including Search & Evaluation, Transactions, Analytics, and Clinical Strategy - and successfully in-licensed five oncology assets within two years.
Earlier in his career at AstraZeneca, Ro was a core member of the Oncology Business Development team. He was a key contributor to many Business Development transactions ranging from in-licensing to divestments and also clinical collaborations to support AstraZeneca’s key franchises. Highlights include leading the $300 million divestment of rare disease therapy Caprelsa to Sanofi/Genzyme, and playing a pivotal role in initiating the landmark $6.9 billion collaboration with Daiichi Sankyo for the HER2-ADC trastuzumab deruxtecan (now Enhertu), an ADC which has since changed Standard of Care in numerous indications. He also led multiple clinical collaborations to support the lifecycle management of PD-L1 inhibitor Imfinzi, including with TROP2-ADC sacituzumab govitecan (now Trodelvy) from Immunomedics (since sold to Gilead for $21bn), and AstraZeneca’s oral SERD AZD9833 Camizestrant (now with a positive Phase 3) and injectable SERD Faslodex in breast cancer.
Ro holds a PhD in Oncology from Trinity College, University of Cambridge, where he was a Gates Scholar, and an MBA from the Cambridge Judge Business School. He also earned a Bachelor of Science (Honours) and a Bachelor of Biomedical Science from the University of Melbourne, Australia.
Ro is a seasoned industry leader and brings over 15 years of experience in Business Development roles across the Pharma, Biotech, and HealthTech sectors. His career includes multiple leadership roles, with a consistent track record of executing transformative deals that have helped shape Standards of Care in Oncology.
At BeiGene, where Pi Health was originally incubated, Ro led Commercial and Business Development within the Applied Innovation Group. Prior to that, as Vice President and Head of Business Development at Ellipses Pharma, he built out key functions - including Search & Evaluation, Transactions, Analytics, and Clinical Strategy - and successfully in-licensed five oncology assets within two years.
Earlier in his career at AstraZeneca, Ro was a core member of the Oncology Business Development team. He was a key contributor to many Business Development transactions ranging from in-licensing to divestments and also clinical collaborations to support AstraZeneca’s key franchises. Highlights include leading the $300 million divestment of rare disease therapy Caprelsa to Sanofi/Genzyme, and playing a pivotal role in initiating the landmark $6.9 billion collaboration with Daiichi Sankyo for the HER2-ADC trastuzumab deruxtecan (now Enhertu), an ADC which has since changed Standard of Care in numerous indications. He also led multiple clinical collaborations to support the lifecycle management of PD-L1 inhibitor Imfinzi, including with TROP2-ADC sacituzumab govitecan (now Trodelvy) from Immunomedics (since sold to Gilead for $21bn), and AstraZeneca’s oral SERD AZD9833 Camizestrant (now with a positive Phase 3) and injectable SERD Faslodex in breast cancer.
Ro holds a PhD in Oncology from Trinity College, University of Cambridge, where he was a Gates Scholar, and an MBA from the Cambridge Judge Business School. He also earned a Bachelor of Science (Honours) and a Bachelor of Biomedical Science from the University of Melbourne, Australia.
Hayes Kim
Senior Technology Advisor
Hayes Kim, as the Chief Development Officer of Pi Health since April 2024, is a pivotal figure in advancing the company's mission in health technology and clinical research. Based in the Los Angeles Metropolitan Area, his expertise is crucial in Pi Health's commitment to revolutionizing global access to innovative medicines and clinical trials, ensuring patients worldwide have equal access to the highest quality of care and research.
In his role at Pi Health, Kim is responsible for aligning the product vision with technical capabilities, driving the execution of the product roadmap, and establishing a model for customer obsession. His work focuses on developing a comprehensive, end-to-end technology platform that streamlines clinical trials, reduces costs, and improves patient outcomes.
Prior to joining Pi Health, Kim served as the SVP of Engineering at AuditBoard from July 2019 to July 2023. At AuditBoard, he led the growth and scaling of their next-generation GRC SaaS Platform, managing product engineering, infrastructure, information security, and IT organizations during a critical phase of company growth. During his tenure, platform revenue grew from $17M to $170M+. In July 2024, AuditBoard exited via acquisition to HG for over $3B.
Hayes' career includes a significant tenure at Verizon Digital Media Services, where he held the position of Vice President of Engineering from January 2016 to July 2019. In this role, he led product and engineering teams responsible for building EdgeCast, the next-generation Edge network, the 2nd largest of it's kind in the world.
Before his time at Verizon, Kim held various roles in product management and development at companies such as the Rubicon Project, Experian Marketing Services, and Lunch.com. These experiences contributed to his broad knowledge across SaaS, PaaS, and IaaS domains in areas including edge computing, content delivery, big data, mobile technology, digital video, online advertising, e-commerce, and social media.
Throughout his career, Kim has authored a total of six patents, several of which have helped define industry best practices for online video, content delivery, and web security. His ability to dive deep technically while also operating broadly at a high level has been a hallmark of his professional journey.
Hayes' educational background includes a B.A. from UCLA in Economics and Computing. Since March 2018, he has been an active member of the LA CTO Forum, contributing to the vibrant tech community in Los Angeles.
Hayes Kim's career trajectory showcases his exceptional ability to blend deep technical knowledge with strategic business acumen, making him an integral part of Pi Health's leadership in driving technological innovation in health technology and clinical research.
In his role at Pi Health, Kim is responsible for aligning the product vision with technical capabilities, driving the execution of the product roadmap, and establishing a model for customer obsession. His work focuses on developing a comprehensive, end-to-end technology platform that streamlines clinical trials, reduces costs, and improves patient outcomes.
Prior to joining Pi Health, Kim served as the SVP of Engineering at AuditBoard from July 2019 to July 2023. At AuditBoard, he led the growth and scaling of their next-generation GRC SaaS Platform, managing product engineering, infrastructure, information security, and IT organizations during a critical phase of company growth. During his tenure, platform revenue grew from $17M to $170M+. In July 2024, AuditBoard exited via acquisition to HG for over $3B.
Hayes' career includes a significant tenure at Verizon Digital Media Services, where he held the position of Vice President of Engineering from January 2016 to July 2019. In this role, he led product and engineering teams responsible for building EdgeCast, the next-generation Edge network, the 2nd largest of it's kind in the world.
Before his time at Verizon, Kim held various roles in product management and development at companies such as the Rubicon Project, Experian Marketing Services, and Lunch.com. These experiences contributed to his broad knowledge across SaaS, PaaS, and IaaS domains in areas including edge computing, content delivery, big data, mobile technology, digital video, online advertising, e-commerce, and social media.
Throughout his career, Kim has authored a total of six patents, several of which have helped define industry best practices for online video, content delivery, and web security. His ability to dive deep technically while also operating broadly at a high level has been a hallmark of his professional journey.
Hayes' educational background includes a B.A. from UCLA in Economics and Computing. Since March 2018, he has been an active member of the LA CTO Forum, contributing to the vibrant tech community in Los Angeles.
Hayes Kim's career trajectory showcases his exceptional ability to blend deep technical knowledge with strategic business acumen, making him an integral part of Pi Health's leadership in driving technological innovation in health technology and clinical research.
Stacey Gibilisco
Head of Human Resources
Stacey Gibilisco, Head of Human Resources at Pi Health, oversees all aspects of the company’s HR function, including employee relations, talent strategy, benefits, and organizational operations. With more than 20 years of experience across healthcare, pharmaceuticals, and life sciences, Stacey brings deep expertise in full-cycle recruitment, physician relations, and sales leadership. She has a proven track record of designing and executing people-focused initiatives that fuel business growth, strengthen employee engagement, and support a purpose-driven culture.
Before joining Pi Health, Stacey was part of BeiGene’s Talent Acquisition team and later served as the Director of External Engagement. She also managed recruitment efforts for top biopharma clients at IQVIA and spent over a decade leading physician engagement at Hackensack Meridian Health. Earlier in her career, she held commercial and recruiting positions at Johnson & Johnson and Pfizer, building a well-rounded foundation in field operations and talent development.
Stacey’s diverse background informs a people-first HR philosophy that supports performance, inclusion, and innovation. She also leads Pi Health’s employee benefit programs, ensuring they evolve with the needs of a growing and engaged workforce. Stacey holds a Bachelor of Science in Public Health Administration from Richard Stockton College of New Jersey and enjoys spending time at the Jersey Shore with her family.
Before joining Pi Health, Stacey was part of BeiGene’s Talent Acquisition team and later served as the Director of External Engagement. She also managed recruitment efforts for top biopharma clients at IQVIA and spent over a decade leading physician engagement at Hackensack Meridian Health. Earlier in her career, she held commercial and recruiting positions at Johnson & Johnson and Pfizer, building a well-rounded foundation in field operations and talent development.
Stacey’s diverse background informs a people-first HR philosophy that supports performance, inclusion, and innovation. She also leads Pi Health’s employee benefit programs, ensuring they evolve with the needs of a growing and engaged workforce. Stacey holds a Bachelor of Science in Public Health Administration from Richard Stockton College of New Jersey and enjoys spending time at the Jersey Shore with her family.
Board of Directors
Brenton Fargnoli, MD
Board Director General Partner, AlleyCorp
Brenton is a General Partner leading the Healthcare team at AlleyCorp, where he leads investments and incubations across digital health with a particular focus on value-based care and physician entrepreneurship. Prior to AlleyCorp, Brenton was an executive at Flatiron Health (acquired by Roche), where he built its value-based care business from the ground up and was instrumental in the launch of OneOncology (acquired by AmerisourceBergen). He worked previously at J.P. Morgan and Blue Cross & Blue Shield. An avid supporter of the New York healthcare ecosystem, Brenton serves on the boards of Fund for Public Health NYC and Digital Health New York.
Board-certified in Internal Medicine, Brenton previously practiced at Memorial Sloan Kettering and completed residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning an MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School.
Board-certified in Internal Medicine, Brenton previously practiced at Memorial Sloan Kettering and completed residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning an MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School.
Rohan Ganesh
Board Director Partner, Obvious Ventures
Rohan invests in mission-driven team building companies that transform pharma operations and catalyze biological breakthroughs.
Prior to joining Obvious, he led venture investments in biotech, diagnostics, and healthcare technology companies at Verily Life Sciences, a Google spinout, and at Northpond Ventures, a life-sciences focused venture firm. He started his career in product management roles at CompuGroup Medical, building electronic medical records, and at Verily, productizing neural networks for diagnostic applications.
Rohan studied Biological Sciences at the University of Oxford and earned an MBA from Harvard Business School.
Prior to joining Obvious, he led venture investments in biotech, diagnostics, and healthcare technology companies at Verily Life Sciences, a Google spinout, and at Northpond Ventures, a life-sciences focused venture firm. He started his career in product management roles at CompuGroup Medical, building electronic medical records, and at Verily, productizing neural networks for diagnostic applications.
Rohan studied Biological Sciences at the University of Oxford and earned an MBA from Harvard Business School.
Vishal Vasishth
Board Observer, Co-Founder and Managing Director, Obvious Ventures
Vishal invests in values-driven founders and companies that dramatically improve healthcare outcomes, create more human-centered financial systems, and reimagine consumer services from the ground up.
He leads Obvious’ investments in full-stack healthcare with Virta, Galileo, and Devoted Health; financial technology startups such as Hedvig, One, Corvus, and Openly; and purpose-led consumer services like Good Eggs and Block Renovation.
Before co-founding Obvious, Vishal was the founding partner of Indian-based fund SONG Investment Advisors. He also served as a senior executive at Steve Case’s Revolution, LLC. Prior to his career as an investor, Vishal spent a decade at outdoor gear and apparel retailer Patagonia, in roles ranging from product manager to Chief Strategy Officer. He was selected as a Henry Crown Fellow of the Aspen Institute and a Next Generation Fellow of the American Assembly, both recognizing value-based leadership. Vishal earned a B. Tech degree in India, an MS from North Carolina State University, and an MBA from UCLA’s Anderson School of Management.
He leads Obvious’ investments in full-stack healthcare with Virta, Galileo, and Devoted Health; financial technology startups such as Hedvig, One, Corvus, and Openly; and purpose-led consumer services like Good Eggs and Block Renovation.
Before co-founding Obvious, Vishal was the founding partner of Indian-based fund SONG Investment Advisors. He also served as a senior executive at Steve Case’s Revolution, LLC. Prior to his career as an investor, Vishal spent a decade at outdoor gear and apparel retailer Patagonia, in roles ranging from product manager to Chief Strategy Officer. He was selected as a Henry Crown Fellow of the Aspen Institute and a Next Generation Fellow of the American Assembly, both recognizing value-based leadership. Vishal earned a B. Tech degree in India, an MS from North Carolina State University, and an MBA from UCLA’s Anderson School of Management.
Michael Schoen
Board Director Strategic Advisor and Special Assistant to CEO, BeiGene
Michael joined BeiGene in 2017 and serves as Strategic Advisor and Special Assistant to the CEO. In addition, Michael oversees Global IT, Global Workplace Services, and U.S. Government Affairs. Prior to that he was Chief of Staff and Special Advisor to the CEO as well as SVP, Business Operations, overseeing Global HR, Global IT, Global Workplace Services, and U.S. Corporate Communications. In all those roles Michael works closely with John V. Oyler and other senior management to help direct BeiGene’s operations and work to meet its goals.
In addition, Michael serves as BeiGene’s representative on the board of Pi Health Inc., an oncology-focused health technology and clinical research company, previously a wholly owned subsidiary of BeiGene spun off in 2024.Before joining BeiGene, Michael was a Managing Director and the Regional Head of Latin America and Caribbean Debt Capital Markets and Derivative Solutions for Scotiabank, based in New York. In this capacity, he was responsible for overseeing the origination and execution of all debt and derivative transactions from and within the region. Michael joined Scotiabank in early 2013 after twelve years in a similar capacity at Credit Suisse. Michael joined Credit Suisse in 2000 when the bank merged with Donaldson, Lufkin & Jenrette, where he was a member of the High Yield Capital Markets group. Prior to that, Michael worked at J.P. Morgan and Lehman Brothers, respectively, in their Emerging Markets groups.
Michael graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Management from the Sloan School of Management. Michael is Chairman of the Board of Directors for HealthCare Chaplaincy Network, Inc., a leader in the research, education, and practice of spirituality within health care and palliative care, as well as . He also serves on the Board of Trustees of BioNJ, the life sciences trade association for New Jersey. Michael grew up in Ohio and has long been a supporter of The Ohio State University’s James Cancer Center through Pelotonia, a cancer fundraising ride. In 2023 he was awarded the Pelotonia Legacy Award, in part for raising over $1.1M over the past fourteen years to support cancer research.
In addition, Michael serves as BeiGene’s representative on the board of Pi Health Inc., an oncology-focused health technology and clinical research company, previously a wholly owned subsidiary of BeiGene spun off in 2024.Before joining BeiGene, Michael was a Managing Director and the Regional Head of Latin America and Caribbean Debt Capital Markets and Derivative Solutions for Scotiabank, based in New York. In this capacity, he was responsible for overseeing the origination and execution of all debt and derivative transactions from and within the region. Michael joined Scotiabank in early 2013 after twelve years in a similar capacity at Credit Suisse. Michael joined Credit Suisse in 2000 when the bank merged with Donaldson, Lufkin & Jenrette, where he was a member of the High Yield Capital Markets group. Prior to that, Michael worked at J.P. Morgan and Lehman Brothers, respectively, in their Emerging Markets groups.
Michael graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Management from the Sloan School of Management. Michael is Chairman of the Board of Directors for HealthCare Chaplaincy Network, Inc., a leader in the research, education, and practice of spirituality within health care and palliative care, as well as . He also serves on the Board of Trustees of BioNJ, the life sciences trade association for New Jersey. Michael grew up in Ohio and has long been a supporter of The Ohio State University’s James Cancer Center through Pelotonia, a cancer fundraising ride. In 2023 he was awarded the Pelotonia Legacy Award, in part for raising over $1.1M over the past fourteen years to support cancer research.
Geoff Kim, MD
Board Director Co-Founder, CEO of Pi Health
Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of Pi Health, a healthcare technology company launched in 2021 whose mission is to drive innovation to enable patients all over the world to have equal access to the highest quality of care and research. He has over 25 years of experience in oncology drug development, regulation, and precision medicine.
As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.
Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.
As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.
Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.
Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.
Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.
Bobby Reddy, MD
Board Director Co-Founder, COO of Pi Health
Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world. Previously, he served in leadership positions at BeiGene and AstraZeneca. At BeiGene, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.
Kevin Ryan
Board Advisor Founder & CEO, AlleyCorp
Often called the “Godfather of NYC tech,” Kevin Ryan is one of the leading internet entrepreneurs and investors in New York. He is a co-founder of MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, Pearl Health, and Transcend Therapeutics, and founds and actively invests in new companies with AlleyCorp every year. Kevin currently serves on 10 company boards.
Earlier in his career, Kevin helped to grow DoubleClick first as President and then as CEO, leading their growth from a 20-person startup to a publicly-traded global leader with over 1,500 employees, through IPO in 1998, and acquisition by Google in 2007.
Kevin has been a civic leader in New York at the city and state level. Appointed by Governor Cuomo, he served on a three-member Fast Food Wage Board that successfully advocated for a wage increase for the state’s fast food workers. Kevin was also a member of the state’s Backend Expenses Commission, advising on spending and enhancing efficiencies, as well as the MTA commission focused on engaging startups and new technologies to improve accessibility and congestion challenges in New York. Additionally, Kevin served on the board of the Trust for Governors Island.
Kevin serves on the Board of Tech:NYC, where he is a founding member and chairs the Policy Committee. He is also the Vice Chairman of The Partnership for New York City, a Director Emeritus at Human Rights Watch, and a member of the Council on Foreign Relations. Previously, Kevin held positions on the boards of Yale University, Yale University Press, INSEAD, Mercy Corps, The NYC Investment Fund, the advisory board of Doctors Without Borders, and the Yale International Council.
Actively engaged in philanthropy, Kevin and his wife Pascaline Servan-Schreiber support organizations including University of the People, The Marshall Project, MLT, Endeavor, Fund for Public Health in NYC, and the Center for Mindful Learning. He continues to be one of the leading funders of the Yale Program for Psychedelic Science. AlleyCorp also invests out of a dedicated Social Impact vertical, which funds both for-profit companies and nonprofit entities dedicated to building technology solutions for low-income and underserved families.
Kevin has been recognized as Entrepreneur of the Year by Ernst & Young, LLP, featured as one of The 100 Most Influential New Yorkers of the Past 25 Years by The Observer, and named one of the 50 Most Influential Business People by Crain’s New York Business, where he was later inducted into the Hall of Fame.
Earlier in his career, Kevin helped to grow DoubleClick first as President and then as CEO, leading their growth from a 20-person startup to a publicly-traded global leader with over 1,500 employees, through IPO in 1998, and acquisition by Google in 2007.
Kevin has been a civic leader in New York at the city and state level. Appointed by Governor Cuomo, he served on a three-member Fast Food Wage Board that successfully advocated for a wage increase for the state’s fast food workers. Kevin was also a member of the state’s Backend Expenses Commission, advising on spending and enhancing efficiencies, as well as the MTA commission focused on engaging startups and new technologies to improve accessibility and congestion challenges in New York. Additionally, Kevin served on the board of the Trust for Governors Island.
Kevin serves on the Board of Tech:NYC, where he is a founding member and chairs the Policy Committee. He is also the Vice Chairman of The Partnership for New York City, a Director Emeritus at Human Rights Watch, and a member of the Council on Foreign Relations. Previously, Kevin held positions on the boards of Yale University, Yale University Press, INSEAD, Mercy Corps, The NYC Investment Fund, the advisory board of Doctors Without Borders, and the Yale International Council.
Actively engaged in philanthropy, Kevin and his wife Pascaline Servan-Schreiber support organizations including University of the People, The Marshall Project, MLT, Endeavor, Fund for Public Health in NYC, and the Center for Mindful Learning. He continues to be one of the leading funders of the Yale Program for Psychedelic Science. AlleyCorp also invests out of a dedicated Social Impact vertical, which funds both for-profit companies and nonprofit entities dedicated to building technology solutions for low-income and underserved families.
Kevin has been recognized as Entrepreneur of the Year by Ernst & Young, LLP, featured as one of The 100 Most Influential New Yorkers of the Past 25 Years by The Observer, and named one of the 50 Most Influential Business People by Crain’s New York Business, where he was later inducted into the Hall of Fame.
